Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)
Public ClinicalTrials.gov record NCT00684918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, 2-Stage, Phase II Study of Single-Agent Obatoclax Mesylate Administered For Three Consecutive Days Every 2 Weeks to Older Patients With Previously Untreated Acute Myeloid Leukemia (AML)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This protocol will evaluate the efficacy of obatoclax in older patients with previously untreated AML.
Study identification
- NCT ID
- NCT00684918
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 18 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 70 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2008
- Primary completion
- Jul 31, 2009
- Completion
- Nov 30, 2009
- Last update posted
- Aug 25, 2013
2008 – 2009
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwestern University | Chicago | Illinois | 60611 | — |
| The University of Iowa | Iowa City | Iowa | 52242 | — |
| University of Kansas Medical Center Research Institute | Westwood | Kansas | 66205 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| St. Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Michigan State University - Breslin Cancer Center | Lansing | Michigan | 48910 | — |
| St. Vincent's Comprehensive Cancer Center | New York | New York | 10011 | — |
| Legacy Emanuel Hospital & Health Center | Portland | Oregon | 97210 | — |
| Penn State Hershey Cancer Institute-Clinical Trials Office | Hershey | Pennsylvania | 17033 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Benaroya Research Institute at Virginia Mason | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00684918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2013 · Synced Sep 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00684918 live on ClinicalTrials.gov.